PANTOSAN-DSR

Comprehensive Product Profile: Pantosan-DSR

Pantosan-DSR, manufactured by Solvista Healthcare, is a fixed-dose combination medication designed for the comprehensive management of gastrointestinal disorders related to excessive acid production and impaired gastric motility. The formulation combines two potent active pharmaceutical ingredients: Pantoprazole Sodium (Enteric Coated) and Domperidone (Sustained Release).

Composition and Mechanism of Action

The effectiveness of Pantosan-DSR lies in its dual-action approach to digestive health, addressing both the chemical (acid) and mechanical (movement) aspects of the gastrointestinal tract.

1. Pantoprazole Sodium (Enteric Coated)

Pantoprazole belongs to a class of drugs known as Proton Pump Inhibitors (PPIs). It works by irreversibly inhibiting the $H^+/K^+$-ATPase enzyme system (the “proton pump”) located at the secretory surface of the gastric parietal cell. By blocking this final step of acid production, it significantly reduces the amount of acid in the stomach.

• Enteric Coating (EC): This is a critical feature of the formulation. Pantoprazole is acid-labile, meaning it would be degraded by stomach acid before it could be absorbed. The enteric coating ensures the capsule passes through the stomach intact and dissolves only in the alkaline environment of the small intestine, maximizing bioavailability.

2. Domperidone (Sustained Release)

Domperidone is a dopamine antagonist with potent gastrokinetic and anti-emetic properties. It increases lower esophageal sphincter pressure, improves antroduodenal coordination, and facilitates gastric emptying.

• Sustained Release (SR): The SR technology allows for a gradual release of Domperidone into the bloodstream over an extended period. This ensures consistent “gastric motility” support throughout the day, preventing the common “peak and trough” effect of immediate-release medications.

Therapeutic Indications

As highlighted in the product literature, Pantosan-DSR is specifically indicated for:

• Gastroesophageal Reflux Disease (GERD): Providing relief from chronic heartburn and preventing damage to the esophagus caused by acid reflux.
• Acid-Related Disorders: Including peptic ulcers, Zollinger-Ellison syndrome, and erosive esophagitis.
• Associated Nausea and Vomiting: Domperidone specifically addresses the feeling of sickness or fullness often associated with acid reflux.
• Bloating and Gastric Stasis: By improving the rate at which the stomach empties, the medication reduces feelings of heaviness and upper abdominal discomfort.

Key Product Benefits

1. Effective Acid Suppression: The PPI component offers superior control over stomach acid compared to traditional antacids or H2 blockers.
2. Enhanced Gastric Motility: The prokinetic action of Domperidone ensures that food and acid move downward through the digestive tract rather than refluxing upward.
3. Rapid and Long-Lasting Relief: The combination provides quick symptomatic relief from heartburn while maintaining control for up to 24 hours.
4. Improved Patient Compliance: By combining two essential treatments into a single capsule, it simplifies the dosage regimen for patients who would otherwise need to take multiple pills.